Hanmi Pharmaceutical said on the 26th that it presented preclinical research results on a targeted anticancer investigational drug under development at a recent international conference in the United States on RAS-targeted new drug development. Hanmi Pharmaceutical's anticancer investigational drug works on the principle of preventing gene mutations from growing into cancer. The company noted it is focusing not only on obesity drugs but also on anticancer investigational drugs.
The anticancer investigational drug HM101207 targets KRAS mutations. KRAS mutations are gene mutations that cause lethal cancers. KRAS mutations are known to be found mainly in patients with pancreatic, colorectal, and lung cancers. The investigational anticancer drug works by suppressing KRAS so it does not progress into cancer.
This anticancer investigational drug blocks the binding of KRAS with SOS1, a protein involved in signal transduction. The company believes the investigational anticancer drug can bind to various KRAS mutations and prevent them from becoming cancer. It said the new drug can be used in global combination therapy strategies for anticancer treatment.
Noh Young-su, director of the ONCO Clinical Team at Hanmi Pharmaceutical, said, "Oncology is a core pillar of Hanmi's new drug development," adding, "We will push ahead with clinical trials for targeted anticancer investigational drugs by concentrating our research and development capabilities."